Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates

od Staudacher, Alexander H, Liapis, Vasilios, Brown, Michael P
izdano v Antib Ther (2018)

Zoledronic Acid Inhibits Both the Osteolytic and Osteoblastic Components of Osteosarcoma Lesions in a Mouse Model

od Labrinidis, Agatha, Hay, Shelley, Liapis, Vasilios, Ponomarev, Vladimir, Findlay, David M., Evdokiou, Andreas
izdano v Clin Cancer Res (2009)

Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®

od Liapis, Vasilios, Tieu, William, Rudd, Stacey E., Donnelly, Paul S., Wittwer, Nicole L., Brown, Michael P., Staudacher, Alexander H.
izdano v EJNMMI Radiopharm Chem (2020)

Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo

od Zinonos, Irene, Labrinidis, Agatha, Lee, Michelle, Liapis, Vasilios, Hay, Shelley, Ponomarev, Vladimir, Diamond, Peter, Findlay, David M, Zannettino, Andrew CW, Evdokiou, Andreas
izdano v J Bone Miner Res (2011)

Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer

od Zinonos, Irene, Labrinidis, Agatha, Lee, Michelle, Liapis, Vasilios, Hay, Shelley, Ponomarev, Vladimir, Diamond, Peter, Zannettino, Andrew C.W., Findlay, David M., Evdokiou, Andreas
izdano v Mol Cancer Ther (2009)

Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer...

od Zysk, Aneta, DeNichilo, Mark O., Panagopoulos, Vasilios, Zinonos, Irene, Liapis, Vasilios, Hay, Shelley, Ingman, Wendy, Ponomarev, Vladimir, Atkins, Gerald, Findlay, David, Zannettino, Andrew, Evdokiou, Andreas
izdano v Cancer Lett (2016)

HYPOXIA-ACTIVATED PRO-DRUG TH-302 EXHIBITS POTENT TUMOUR SUPPRESSIVE ACTIVITY AND COOPERATES WITH CHEMOTHERAPY AGAINST OSTEOSARCOMA

od Liapis, Vasilios, Labrinidis, Agatha, Zinonos, Irene, Hay, Shelley, Ponomarev, Vladimir, Panagopoulos, Vasilios, DeNichilo, Mark, Ingman, Wendy, Atkins, Gerald J., Findlay, David M., Zannettino, Andrew CW., Evdokiou, Andreas
izdano v Cancer Lett (2014)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models

od Liapis, Vasilios, Zinonos, Irene, Labrinidis, Agatha, Hay, Shelley, Ponomarev, Vladimir, Panagopoulos, Vasilios, Zysk, Aneta, DeNichilo, Mark, Ingman, Wendy, Atkins, Gerald J., Findlay, David M., Zannettino, Andrew C. W., Evdokiou, Andreas
izdano v Cancer Med (2016)

Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma

od Labrinidis, Agatha, Diamond, Peter, Martin, Sally, Hay, Shelley, Liapis, Vasilios, Zinonos, Irene, Sims, Natalie A., Atkins, Gerald J., Vincent, Cristina, Ponomarev, Vladimir, Findlay, David M., Zannettino, Andrew C.W., Evdokiou, Andreas
izdano v Clin Cancer Res (2009)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma

od Liapis, Vasilios, Zysk, Aneta, DeNichilo, Mark, Zinonos, Irene, Hay, Shelley, Panagopoulos, Vasilios, Shoubridge, Alexandra, Difelice, Christopher, Ponomarev, Vladimir, Ingman, Wendy, Atkins, Gerald J., Findlay, David M., Zannettino, Andrew C. W., Evdokiou, Andreas
izdano v Cancer Med (2017)

Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer

od ZINONOS, IRENE, LUO, KE-WANG, LABRINIDIS, AGATHA, LIAPIS, VASILIOS, HAY, SHELLEY, PANAGOPOULOS, VASILIOS, DENICHILO, MARK, KO, CHUN-HAY, YUE, GRACE GAR-LEE, LAU, CLARA BIK-SAN, INGMAN, WENDY, PONOMAREV, VLADIMIR, ATKINS, GERALD J., FINDLAY, DAVID M., ZANNETTINO, ANDREW C.W., EVDOKIOU, ANDREAS
Izdano 2014